IRIS
PAOLICELLI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.652
EU - Europa 1.133
AS - Asia 706
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
SA - Sud America 2
Totale 7.503
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.634
CN - Cina 430
SE - Svezia 374
IT - Italia 259
SG - Singapore 224
FI - Finlandia 108
UA - Ucraina 99
DE - Germania 97
GB - Regno Unito 88
BE - Belgio 33
FR - Francia 31
VN - Vietnam 21
CA - Canada 17
IN - India 11
CZ - Repubblica Ceca 7
NL - Olanda 7
IR - Iran 6
SA - Arabia Saudita 6
EU - Europa 4
HK - Hong Kong 4
IE - Irlanda 4
LT - Lituania 4
RU - Federazione Russa 4
AU - Australia 3
BG - Bulgaria 3
PT - Portogallo 3
A1 - Anonimo 2
ES - Italia 2
GR - Grecia 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
BR - Brasile 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
HR - Croazia 1
IS - Islanda 1
JP - Giappone 1
KZ - Kazakistan 1
MK - Macedonia 1
PA - Panama 1
PL - Polonia 1
UZ - Uzbekistan 1
Totale 7.503
Salva come PNG Salva come JPEG
Città #
Fairfield 893
Woodbridge 603
Chandler 539
Houston 415
Ashburn 405
Seattle 393
Cambridge 311
Wilmington 299
Nyköping 298
Ann Arbor 224
Jacksonville 224
Singapore 172
Lawrence 119
Roxbury 114
Beijing 102
Nanjing 94
Bari 82
Boardman 73
Des Moines 72
Princeton 68
New York 65
Inglewood 49
San Diego 38
Brooklyn 37
Brussels 33
Munich 28
Santa Clara 27
Helsinki 25
Nanchang 25
Shenyang 24
London 21
Dong Ket 20
Norwalk 20
Tianjin 18
Hebei 17
Jiaxing 17
Los Angeles 17
Guangzhou 16
Paris 15
Bisceglie 13
Wuhan 12
Marseille 10
Mottola 10
Toronto 10
Pune 9
Redwood City 9
Shanghai 9
Changsha 8
Brno 7
Dearborn 7
Milan 7
Jinan 6
Rome 6
Taranto 6
Washington 6
Catania 5
Hefei 5
Jeddah 5
Monmouth Junction 5
San Mateo 5
Augusta 4
Dublin 4
Grottaglie 4
Hanover 4
Hong Kong 4
Jinhua 4
Kilburn 4
Ningbo 4
Ottawa 4
Senigallia 4
Ardabil 3
Frankfurt am Main 3
Lviv 3
Romola 3
San Francisco 3
Trani 3
Villacidro 3
Wuxi 3
Yiwu 3
Zhengzhou 3
Amsterdam 2
Bolsena 2
Chicago 2
Dalian 2
Edmonton 2
Florence 2
Grafing 2
Gravina in Puglia 2
Hangzhou 2
Hounslow 2
Imbersago 2
Indiana 2
Islington 2
Jesi 2
Kansas City 2
New Bedfont 2
Nutley 2
Palermo 2
Phoenix 2
Redmond 2
Totale 6.282
Salva come PNG Salva come JPEG
Nome #
Prognostic indicators in pediatric clinically isolated syndrome 133
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 132
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 131
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 124
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 109
null 109
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 109
A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B 109
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 107
Age-related changes of serum N-acetyl-aspartate in healthy controls. 106
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 106
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 101
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 99
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 97
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 95
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 94
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 93
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 92
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 92
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 92
Age-related disability in multiple sclerosis 91
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 91
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 90
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 89
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 88
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 86
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 85
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 83
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 82
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 79
Predictors of disability worsening in clinically isolated syndrome 78
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. 76
Atypical forms of Multiple Sclerosis or different phases of a same disease? 75
null 73
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 73
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. 73
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 71
null 71
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 71
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 71
null 68
null 68
Low serum urate levels are associated to female gender in multiple sclerosis patients. 68
null 67
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 67
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 66
null 65
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 65
null 64
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 62
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. 62
null 62
null 60
Variations of the perforin gene in patients with multiple sclerosis. 60
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 59
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients 58
null 58
null 58
null 55
null 55
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 54
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy 54
null 53
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 53
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 52
null 52
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. 52
Geographical variations in sex ratio trends over time in multiple sclerosis. 51
null 51
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 50
null 50
null 50
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 50
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 49
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 48
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 47
The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. 47
The IFN beta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy 46
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 46
Immunomodulatory therapies delay disease progression in multiple sclerosis. 46
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 45
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 45
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid of demyelinating disease of the central and peripheral nervous system 44
IFNB-1B TREATMENT EFFECTS ON SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 SERUM LEVELS AND T-CELL SUBSETS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS. 12TH CONGRESS OF THE EUROPEAN COMMITTE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) 44
null 44
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 44
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 41
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 41
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 39
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 39
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 39
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 38
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 37
VALUTAZIONE POST-MARKETING DI SICUREZZA DELL' INTERFERONE-BETA (IFN-BETA) IN PAZIENTI CON SCLEROSI MULTIPLA (SM) RELAPSING-REMITTING (RR) NELL' ITALIA MERIDIONALE. RICERCA SCIENTIFICA DELLE 36
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 36
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 36
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 34
EFFETTI ANTINFIAMMATORI DELL’ INTERFERONE BETA-1B RICOMBINANTE NELLA SCLEROSI MULTIPLA: STUDIO LONGITUDINALE DEI LIVELLI SIERICI DELLA FORMA SOLUBILE DI INTERCELLULAR ADHESION MOLECULE-1 (SICAM-1) E DEI SUBSETS LINFOCITARI 32
Soluble intercellular adhesion molecule-I (sICAM-I) in serum and cerebrospinal fluid of demyelinating diseases of the central and peripheral nervous system 32
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 32
Totale 6.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.649
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.649
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.315 0 0 0 0 187 108 194 200 231 126 224 45
2020/20211.390 104 80 111 113 163 100 132 101 107 166 125 88
2021/2022936 57 109 16 33 44 88 43 46 86 59 173 182
2022/20231.422 229 184 85 134 167 166 17 167 206 5 26 36
2023/2024470 57 68 28 31 39 108 13 18 9 23 6 70
2024/2025542 133 42 186 103 78 0 0 0 0 0 0 0
Totale 7.856